<?xml version="1.0" encoding="UTF-8"?>
<ref id="rep-ref-34954-1">
 <label>1</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Gilbert</surname>
    <given-names>BE</given-names>
   </name>
   <name>
    <surname>Patel</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Lu</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Guebre-Xabier</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Piedra</surname>
    <given-names>PA</given-names>
   </name>
   <name>
    <surname>Glenn</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Ellingsworth</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Smith</surname>
    <given-names>G</given-names>
   </name>
  </person-group>: 
  <article-title>Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.</article-title>
  <source>
   <italic>Vaccine</italic>
  </source>.
  <year>2018</year>;
  <volume>36</volume>(
  <issue>52</issue>) : 
  <elocation-id>10.1016/j.vaccine.2018.10.073</elocation-id>
  <fpage>8069</fpage>-
  <lpage>8078</lpage>
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.10.073</pub-id>
  <?supplied-pmid 30389195?>
  <pub-id pub-id-type="pmid">30389195</pub-id>
 </mixed-citation>
</ref>
